MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Kite Pharma Company Profile (NASDAQ:KITE)

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 14 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $77.50 (51.99% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016MizuhoReiterated RatingBuy$80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Raymond JamesInitiated CoverageOutperform$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2016SunTrustReiterated RatingBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$111.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015GuggenheimReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Credit SuisseReiterated RatingOutperform$79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Kite Pharma (NASDAQ:KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($1.08)($0.60)$4.61 million$5.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.71)($0.54)$4.54 million$4.89 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.64)($0.38)$4.06 million$5.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.40)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115$0.12($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.20)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Kite Pharma (NASDAQ:KITE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.37)($0.93)($1.09)
Q2 20163($1.30)($1.15)($1.24)
Q3 20163($1.71)($1.65)($1.69)
Q4 20163($2.19)($2.05)($2.10)
(Data provided by Zacks Investment Research)
Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Kite Pharma (NASDAQ:KITE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Kite Pharma (NASDAQ:KITE)
DateHeadline
06/27/16 09:10 AMShare Update and Earnings Review for Kite Pharma, Inc. (NASDAQ:KITE) - Press Telegraph
06/26/16 09:35 AMHow Many Kite Pharma Inc (NASDAQ:KITE)'s Analysts Are Bearish? - Press Telegraph
06/25/16 02:21 PM3 Biotech Stocks to Buy in July -
06/24/16 07:29 AMCovering the Bases on Kite Pharma, Inc. (NASDAQ:KITE): Where is the Stock Going? - Press Telegraph
06/24/16 07:29 AMKite Pharma, Inc. (NASDAQ:KITE) Earnings Glance and Target Price Review - Engelwood Daily
06/22/16 09:29 AMKite Pharma Opens Production Facility In El Segundo, California
06/21/16 04:31 PMBRIEF-Kite Pharma expands development of TCR therapies - Reuters
06/21/16 04:31 PMBRIEF-Kite Pharma opens T-Cell therapy manufacturing facility - Reuters
06/21/16 04:31 PMKite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell ... - Area Development Online
06/21/16 09:21 AMBRIEF-Kite Pharma opens T-Cell therapy manufacturing facility
06/20/16 04:40 PMKite Pharma Expands Development of T-Cell Receptor (…
06/20/16 04:19 PMKite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility - [at noodls] - 43,500-Square-Foot Plant Next to Los Angeles International Airport Will Support Production of Engineered CAR and TCR Cancer Immunotherapies Preparations on Track to Launch Lead Product Candidate KTE-C19 ...
06/20/16 07:19 AMKite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI) - [at noodls] - New CRADA with the NCI's Experimental Transplantation and Immunology Branch Accelerates Development of HPV-16 E7 TCR Product Candidate SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (NASDAQ:KITE) ...
06/13/16 07:42 AMStocks Earnings Analysis Report: CDW Corporation (NASDAQ:CDW), Kite Pharma, Inc. (NASDAQ:KITE) - Beacon Chronicle
06/13/16 07:42 AMInsiders See Huge Upside In These Biotechs: Kite Pharma Inc. and Juno Therapeutics Inc. - CML News
06/11/16 04:58 PMRaymond James Initiates Coverage on Kite Pharma Inc to Outperform - Trade Calls
06/10/16 07:42 AMKite Pharma Inc. (KITE) is Trading Higher on Unusual Volume for June 08 - Equities.com
06/08/16 05:10 PMKITE PHARMA INC. (NASDAQ:KITE) Financial Condition Compared to S&P 500 - CML News
06/08/16 01:29 PMKite's next generation cancer therapy -
06/08/16 07:39 AMKite Pharma Inc. (KITE) is Trading Higher on Unusual Volume for June 06 - Equities.com
06/08/16 07:38 AMKite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress - [at noodls] - Results from ZUMA-1 Phase 1 study of KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL) SCHOLAR-1, first meta-analysis of patient-level outcomes in chemorefractory DLBCL, an ...
06/07/16 05:01 PMPerformance Overview of the company: Kite Pharma, Inc. (NASDAQ:KITE) - News Oracle
06/07/16 05:01 PMEarnings in Focus: Kite Pharma, Inc. (NASDAQ:KITE), Skechers U.S.A., Inc. (NYSE:SKX) - Beacon Chronicle
06/07/16 07:26 AMKite Pharma Receives New Rating from Top Analyst - Markets.co
06/07/16 07:26 AMInvestors Targeted Stocks: Tenet Healthcare Corporation (NYSE:THC) , Kite Pharma, Inc. (NASDAQ:KITE) - Street Updates
06/06/16 04:45 PMKite Pharma (KITE) Will Present SCHOLAR-1 Data in Chemorefractory DLBCL at ASCO - StreetInsider.com
06/06/16 04:45 PMMonday's Mid-Day Movers: Kite Pharma Inc (KITE), Uranium Energy (UEC), Transocean LTD (RIG), Halcon Resources ... - Analyst Ratings
06/06/16 04:45 PMKite Pharma Inc (KITE) Stock Gains on Results from Clinical Oncology Studies - Bidness ETC
06/06/16 04:03 PMKITE PHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/06/16 03:42 PMWhy is Kite Pharma (KITE) Stock Soaring Today? -
06/06/16 03:28 PMUS STOCKS-S&P 500 ends at 7-mo high after Yellen comments - [Reuters - UK Focus] - The S&P 500 closed at a 7-month high on Monday as Federal Reserve Chair Janet Yellen painted a mostly upbeat picture of the economy but gave little sense of when a rate hike may be coming. The S&P energy index rose 2 percent, leading gains in the benchmark S&P 500. Yellen's remarks, which were likely her last public comments before a policy meeting next week, followed Friday's dismal monthly jobs report, which raised concerns over the ability of the economy to absorb a rate hike as early as June.
06/06/16 10:20 AMWhy Kite Pharma Shares Vaulted 10.7% Higher in May -
06/06/16 08:28 AMInvestors Targeted Stocks: Tenet Healthcare (THC) , Kite Pharma, (KITE) - Street Updates
06/06/16 08:28 AMBRIEF-Kite Pharma presents responses in Phase 1 of ZUMA-1 in chemorefractory non-Hodgkin lymphoma patients - Reuters
06/06/16 08:28 AMStock Update (NASDAQ:KITE): Kite Pharma Inc Announces the First Meta-Analysis of Outcomes in Chemorefractory ... - Smarter Analyst
06/06/16 08:28 AMCancer cell therapies could be approved next year: Juno, Kite Pharma - Fox News
06/06/16 06:58 AMKite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1) - [at noodls] - Median overall survival was 6.6 months and consistent across subgroups including refractory status, stage of disease and line of therapy Overall response rate was 26% with only 8% achieving a complete ...
06/04/16 04:52 PMCancer cell therapies could be approved next year: Juno, Kite Pharma - Reuters
06/04/16 07:36 AMKite Pharma, Cell Design Labs form research collaboration - L.A. Biz
06/03/16 05:11 PMKite Pharma Inc (KITE) Stock Price Down 4.6% on Insider Selling - Let Me Know About This
06/03/16 07:36 AMShare Rating Focus on Kite Pharma, Inc. (NASDAQ:KITE) - HNN - Share Rating Focus on Kite Pharma, Inc. (NASDAQ:KITE)HNNPresently, Wall Street analysts have given a consensus stock rating of 1 on shares of Kite Pharma, Inc. (NASDAQ:KITE). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
06/03/16 07:36 AMKite Pharma Inc (KITE) Stock Gains on Research Partnership with Cell Design Labs - Bidness ETC - Bidness ETCKite Pharma Inc (KITE) Stock Gains on Research Partnership with Cell Design LabsBidness ETCKite Pharma Inc. (NASDAQ:KITE) shares are on an upward trajectory today, and gained as much as 7.86% around 2:20 PM EDT, after the company announced a research partnership and license agreement with Cell Design Labs, Inc. KITE stock is up over ...Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular 'On/Off Switches' for ...Business Wire (press release)Maxim Group Reaffirms Buy Rating for Kite Pharma Inc (KITE)The Cerbat GemKite Pharma, Inc. (NASDAQ:KITE) Analyst ReviewRisers & FallersStreetInsider.com -Genetic Engineering & Biotechnology News -Franklin Independentall 20 news articles »
06/02/16 05:07 PMKite Pharma, Inc. (NASDAQ:KITE) Rose 2.22% Afterhours: NII Holdings Inc. (NASDAQ:NIHD), Sears Holdings ... - KC Register - Kite Pharma, Inc. (NASDAQ:KITE) Rose 2.22% Afterhours: NII Holdings Inc. (NASDAQ:NIHD), Sears Holdings ...KC RegisterKite Pharma, Inc. (NASDAQ:KITE) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) has granted access to its newly established Priority ...and more »
06/02/16 05:07 PMBRIEF-Kite Pharma and Cell Design Inc collaborate on CAR-T immunotherapy research - Reuters - BRIEF-Kite Pharma and Cell Design Inc collaborate on CAR-T immunotherapy researchReutersArie belldegrun to join board of cell design labs, david chang, evp, research and development, chief medical officer of kite, will join as board observer. * Co, cell design labs, inc announced a research collaboration and license agreement. * To ...
06/02/16 07:42 AMAnalysts Offer Insights on Healthcare Companies: Kite Pharma Inc (NASDAQ: KITE), Biospecifics (NASDAQ: BSTC ... - Analyst Ratings - Analysts Offer Insights on Healthcare Companies: Kite Pharma Inc (NASDAQ: KITE), Biospecifics (NASDAQ: BSTC ...Analyst RatingsThere's a lot to be optimistic about in the Healthcare sector as 2 experts just weighed in on Kite Pharma Inc (NASDAQ: KITE), Biospecifics (NASDAQ: BSTC) and Agile Therapeutics (NASDAQ: AGRX) with bullish sentimens. Kite Pharma Inc (NASDAQ: KITE).
06/02/16 07:42 AMKite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular 'On/Off Switches' for ... - Business Wire (press release) - Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular 'On/Off Switches' for ...Business Wire (press release)SANTA MONICA, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Kite Pharma, Inc. (NASDAQ: KITE) (“Kite”) and Cell Design Labs, Inc. today announced a research collaboration and license agreement to develop next generation, precision-controlled ...Form 8-K Kite Pharma, Inc. For: Jun 01StreetInsider.comCell Design Labs Executes Series of Private FinancingsEIN News (press release)all 3 news articles »
06/02/16 07:25 AMKite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches' for CAR T-Cell Immunotherapies - [at noodls] - Kite to License Cell Design Labs' Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs' Reversible 'On/Off ...
06/02/16 07:11 AMKITE PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/02/16 07:00 AMKite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies - [Business Wire] - Kite Pharma, Inc. and Cell Design Labs, Inc. today announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor product candidates that incorporate Cell Design Labs’ molecular “on/off switch” technology.
06/01/16 05:13 PMBRIEF-Kite Pharma granted priority medicines regulatory support access for KTE-C19 - Reuters - BRIEF-Kite Pharma granted priority medicines regulatory support access for KTE-C19ReutersBRIEF-Kite Pharma granted priority medicines regulatory support access for KTE-C19. June 1 Kite Pharma Inc : * Kite Pharma granted priority medicines regulatory support access for KTE-C19 in treatment of chemorefractory diffuse large b-cell lymphoma ...
About Kite Pharma

Kite Pharma logoKite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company's lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KITE
  • CUSIP:
Key Metrics:
  • Previous Close: $50.99
  • 50 Day Moving Average: $49.64
  • 200 Day Moving Average: $50.15
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $2.51B
  • Current Quarter EPS Consensus Estimate: $-5.60 EPS
Additional Links:
Kite Pharma (NASDAQ:KITE) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha